Perioperative changes in platelet count in patients with atrial septal defect

Akiko Akashi1, Masahiro Kamada1, Naomi Nakagawa1

  • 1Department of Pediatric Cardiology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.

Insights

Platelet counts decrease and mean platelet volume (MPV) increases after atrial septal defect (ASD) closure with the Amplatzer septal occluder (ASO), indicating ongoing platelet changes post-procedure.

Area of Science:

  • Cardiology
  • Hematology
  • Medical Devices

Background:

  • Atrial septal defect (ASD) closure using the Amplatzer septal occluder (ASO) is associated with changes in platelet count and function.
  • The clinical significance of these post-procedural platelet alterations is not fully understood.

Purpose of the Study:

  • To investigate changes in platelet count and mean platelet volume (MPV) before and after ASO placement for ASD closure.
  • To explore the associations between platelet parameters and clinical factors, and to discuss the underlying mechanisms and clinical implications.

Main Methods:

  • Evaluation of 109 patients undergoing ASO placement for ASD.
  • Analysis of platelet count and MPV levels pre- and post-procedure.

Main Results:

  • Younger patients with larger ASDs received larger ASO devices, exhibiting higher rates of platelet count change.
  • Platelet counts decreased by 21.3% within 3 days post-ASO placement and remained lower at one month.
  • MPV significantly increased post-ASO placement and remained elevated at one month.
  • ASO size was the primary factor influencing post-closure platelet count reduction.

Conclusions:

  • A month after ASO placement, decreased platelet counts and increased MPVs suggest ongoing platelet consumption and production.
  • These findings highlight dynamic hematological changes following ASO intervention for ASD.
Abstract

Related Concept Videos

Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
180
Aneurysm IV: Nursing Management01:22

Aneurysm IV: Nursing Management

Vigilant monitoring for aneurysm rupture is essential for patients undergoing aortic surgery.Preoperative Nursing ManagementContinuously monitor the patient for manifestations of aneurysm rupture, such as pallor, weakness, tachycardia, hypotension, abdominal, back, groin, or periumbilical pain, changes in consciousness, and a pulsating abdominal mass. Regularly assess the patient's peripheral pulses.Instruct the patient to consume a clear liquid diet the day before surgery and administer...
282
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.4K
Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
228
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
933